Anti-Hypertensive Drugs - Kenya

Kenya

The Anti-Hypertensive Drugs market in Kenya is projected to reach a revenue of US$9.68m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2028) of -0.16%, resulting in a market volume of US$9.62m by 2028.
When compared globally, United States is anticipated to generate the highest revenue of US$12,290.00m in 2024.
Kenya's pharmaceutical market is witnessing a growing demand for anti-hypertensive drugs due to the increasing prevalence of hypertension in the country.

Key regions: Germany, United States, France, China, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Hypertensive Drugs in Kenya has been increasing steadily in recent years.

Customer preferences: The Kenyan population has been experiencing a rise in non-communicable diseases, including hypertension. This has led to an increase in demand for Anti-Hypertensive Drugs, as more people are seeking treatment for the condition. Additionally, there has been a growing awareness of the importance of preventive healthcare, which has led to more people taking medication to manage their blood pressure.

Trends in the market: The Anti-Hypertensive Drugs market in Kenya is dominated by generic drugs, which are more affordable for the majority of the population. However, there has been a growing trend towards the use of branded drugs, particularly among the middle and upper classes. This is due to the perception that branded drugs are of higher quality and more effective than generic drugs.

Local special circumstances: One of the unique features of the Kenyan market is the role of the National Hospital Insurance Fund (NHIF). The NHIF provides health insurance coverage to a large proportion of the population, including coverage for Anti-Hypertensive Drugs. This has helped to increase access to medication for those who would otherwise not be able to afford it.

Underlying macroeconomic factors: The Kenyan economy has been growing steadily in recent years, with a focus on infrastructure development and investment in key sectors such as healthcare. This has led to an increase in the availability of healthcare services, including access to Anti-Hypertensive Drugs. Additionally, the government has been taking steps to improve the regulatory environment for pharmaceuticals, which has helped to increase the quality and safety of drugs on the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.